EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-SA 4.0

The Use of Platelet-Rich Plasma (PRP) in the Treatment of Achilles Tendinopathy in Athletes: a Review of Current Guidelines

Wiktor Beśka, Michał Kalisiak, Michał Kasznicki, Małgorzata Czechowska, Natalia Micek, Alicja Rogozińska, Jakub Łącki, Emilia Skrzypek, Mikołaj Kamela, Karol Jackowiak

Quality in Sport · 21.06.2026 · 59 · 72786

DOI: 10.12775/qs.2026.59.72786 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Quality in Sport, online erschienen am 21.06.2026. Verfasst von Wiktor Beśka und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To systematically evaluate platelet-rich plasma (PRP) injections for Achilles tendinopathy in athletes based on literature published between 2017 and 2026.

Methods

A systematic PubMed search identified 20 high-quality studies, including RCTs, meta-analyses, and systematic reviews. The analysis focused on clinical outcomes (primarily VISA-A scores) and technical factors, such as cellular composition, injection frequency, and anatomical injury location.

Results

Evaluating data from 697 patients, PRP showed no significant benefit over placebo for midportion tendinopathy (p = 0.085). However, multiple injections (e.g., four) yielded superior tendon remodeling compared to a single dose. PRP demonstrated greater efficacy for insertional tendinopathy and cases unresponsive to standard care. Still, the supporting evidence is statistically fragile (median Fragility Index = 5) and prone to publication bias. Clinically, PRP should not be a first-line treatment for midportion lesions but may be considered for insertional injuries or patients failing to improve after at least six months of conservative management. Repeated, carefully structured injections may be necessary for positive results.

Conclusions

PRP is not recommended as a primary treatment but serves as an auxiliary option for chronic, recalcitrant cases. Due to the lack of uniform protocols and the statistical instability of current evidence, clinicians must exercise considerable caution before routinely adopting PRP in sports medicine.

Zitieren

APA

Beśka, W., Kalisiak, M., Kasznicki, M., Czechowska, M., Micek, N., Rogozińska, A., Łącki, J., Skrzypek, E., Kamela, M., & Jackowiak, K. (2026). The Use of Platelet-Rich Plasma (PRP) in the Treatment of Achilles Tendinopathy in Athletes: a Review of Current Guidelines. Quality in Sport, 59, 72786. https://doi.org/10.12775/qs.2026.59.72786

Vancouver

Beśka W, Kalisiak M, Kasznicki M, Czechowska M, Micek N, Rogozińska A, et al. The Use of Platelet-Rich Plasma (PRP) in the Treatment of Achilles Tendinopathy in Athletes: a Review of Current Guidelines. Quality in Sport. 2026;59:72786. doi:10.12775/qs.2026.59.72786

BibTeX
@article{Beka2026,
  author = {Beśka, Wiktor and Kalisiak, Michał and Kasznicki, Michał and Czechowska, Małgorzata and Micek, Natalia and Rogozińska, Alicja and Łącki, Jakub and Skrzypek, Emilia and Kamela, Mikołaj and Jackowiak, Karol},
  title = {The Use of Platelet-Rich Plasma (PRP) in the Treatment of Achilles Tendinopathy in Athletes: a Review of Current Guidelines},
  journal = {Quality in Sport},
  year = {2026},
  volume = {59},
  pages = {72786},
  doi = {10.12775/qs.2026.59.72786}
}
Kostenlos starten →